ArticleOrphanet journal of rare diseases2025
Patient experience with pulmonary hypertension in Spain.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThis study explores the experiences of patients with pulmonary arterial hypertension (PAH) in Spain, focusing on the impact of patient support programs on disease management and quality of life. This study aimed to evaluate the effectiveness of patient support programs for PAH in improving disease management and quality of life of patients with PAH.
methodsA mixed study was carried out, applying qualitative and quantitative techniques with the aim of exploring and quantifying the experience of participants in support programs for PAH patients. It started with a integrate review of the literature which feed a qualitative phase where 14 patients (all women) diagnosed with PAH at least one year before were involved in focus groups. Subsequently, a quantitative phase was carried out, in which 36 patients, selected by non-probabilistic sampling, participated.
resultsThis study found that support programs substantially improve the quality of life and disease management in patients with PAH. In the qualitative phase, participants reported an improved perception of their ability to manage the disease, attributed to the emotional support and information provided. In the quantitative phase, considerable improvements were observed in several indicators of quality of life and disease management, corroborating the qualitative findings.
conclusionsPatient support programs are essential for improving disease management and the quality of life of patients with PAH. However, the findings highlight a gap in access to emotional and educational support within the healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.